Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

buflomedil

Known as: 2,4,6-trimethoxyphenyl-3-pyrrolidine propyl ketone, blufomedil, 4-(1-pyrrolidinyl)-1-(2,4,6-trimethoxyphenyl)-1-butanone 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (5)

Buflomedil LindoFonzylaneLoftylbuflomedil hydrochloride
Expand

Broader (2)

PyrrolidinesVasodilator Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Long-Term Follow-Up of Hypothenar Hammer Syndrome: A Series of 47 Patients
Hypothenar hammer syndrome (HHS) is an uncommon form of secondary Raynaud phenomenon, occurring mainly in subjects who use the… 
2006
2006
Buflomedil and pentoxifylline in the viability of dorsal cutaneous flaps of rats treated with nicotine.
BACKGROUND Nicotine reduces skin-flap survival. Pharmacologic therapy may represent an alternative treatment strategy to… 
Highly Cited
2005
Highly Cited
2005
Continuous Peripheral Nerve Blocks at Home for Treatment of Recurrent Complex Regional Pain Syndrome I in Children
Background:Recurrent complex regional pain syndrome I is not rare in the pediatric population. The authors conducted this study… 
Highly Cited
2001
Highly Cited
2001
Translocation of drug particles in HPMC matrix gel layer: effect of drug solubility and influence on release rate.
The aim of this work was to study the release mechanisms of drugs having different solubility (buflomedil pyridoxalphosphate 65… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
1995
Highly Cited
1995
Drug diffusion front movement is important in drug release control from swellable matrix tablets.
Swellable controlled release devices of buflomedil pyridoxalphosphate in hydroxypropyl methylcellulose were prepared, and their… 
1991
1991
Increase in Skin‐Flap Survival by the Vasoactive Drug Buflomedil
The effect of buflomedil to protect skin tissue from ischemia and necrosis was studied in random cutaneous flaps. Measurements… 
Review
1987
Review
1987
Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
Pentoxifylline (oxpentifylline) is an orally active haemorheological agent for the treatment of peripheral vascular disease… 
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table II
1984
1984
Buflomedil in Arterial Occlusive Disease: Results of a Controlled Multicenter Study
In a double-blind, randomised multicentre study buflomedil, a vasoactive substance, was compared with placebo in the treatment of… 
  • table I
  • table IV
1981
1981
Effects of Buflomedil on Erythrocyte Deformability
This brief communication outlines re cent experiments on the effects of buflo medil, a new vasoactive agent, on red cell… 
  • table 1
  • table 2
Review
1981
Review
1981
An Experimental Overview of a New Vasoactive Drug: Buflomedil HCl
A brief review of the pharmacology, pharmacokinetics, and metabolism of buf lomedil-HCl is presented providing a phar macologic… 
  • figure 1
  • table 1
  • table 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE